Skip to main content
. 2016 Oct 13;11(10):e0164727. doi: 10.1371/journal.pone.0164727

Fig 6. Effect of TKIs and PDGF-BB (PDGF) on RANKL.

Fig 6

Effect of (A) nilotinib, (B) imatinib, (C) bosutinib and (D) PDGF-BB (PDGF) on expression of RANKL mRNA in primary rat osteoblasts. Gene expression is quantitated relative to the baseline control value. Data are mean ± SEM. In the case of primary rat osteoblasts treated with imatinib, individual time-points were not significantly different from control, thus the p-value for the overall difference between the treatment group and the control group is shown on Fig 6B. nsnot significant, *p<0.05, **p<0.01, ***p<0.001 vs vs untreated control. Effect of nilotinib and imatinib 1 μM on expression of RANKL mRNA in murine bone marrow (Fig 6E). Data are mean ± SEM. Individual time-points were not significantly different from control, thus the p-value for the overall difference between the treatment group and the control group is shown on 6E. nsnot significant vs untreated control. Effect of PDGF 10ng/ml and nilotinib 1.0μM on expression of RANKL mRNA in ST2 cells (Fig 6F). Gene expression is quantitated relative to the appropriate baseline value. Data are mean ± SEM. nsnot significant, **p<0.01, ***p<0.001 vs PDGF/nilotinib-treated group. NIL, nilotinib.